Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, a case of a patient with dermatomyositis and alopecia universalis showed successful treatment with tofacitinib, suggesting potential responsiveness to janus kinase inhibitors.

This source discusses that while oral JAK inhibitors are used for treating lichen planopilaris and frontal fibrosing alopecia, they carry significant risk of adverse events; two cases showed promising results using tofacitinib cream as a safer topical alternative.

This study found that Tideglusib enhances wound healing in aged rats by activating the PI3K/Akt pathway, suggesting its potential for medical and cosmetic applications targeting age-related skin changes.

Tirzepatide may improve hair loss by reducing insulin resistance.

This review describes the approved use and adverse effects of gefitinib in patients with advanced non-small cell lung cancer, without presenting new clinical findings.

In this study, incorporating cetirizine into transferosome formulations significantly enhanced hair growth in mice and boosted IGF-1 and VEGF levels, suggesting that this method could be a promising alternative to traditional hair growth treatments, though further studies are needed to confirm its safety and suitability.

ITK inhibitors may effectively treat alopecia areata.

In this study, tofacitinib and baricitinib showed comparable efficacy and tolerability under unorthodox weight-stratified dosing in pediatric patients with moderate-to-severe alopecia areata over 24 weeks; however, the unorthodox baricitinib regimen yielded a lower effectiveness in severe cases, emphasizing the importance of adherence to guideline-recommended dosing.

This report discusses the FDA's rejection of Aveed, a long-acting testosterone injection, due to safety concerns despite divided advisory committee opinions, without presenting new clinical data.

In this case report, a patient with HIV developed hirsutism after starting tofacitinib for alopecia areata, which resolved upon medication discontinuation and laser hair removal.

This study concluded that oral tofacitinib significantly improved hair growth in patients with alopecia areata, alopecia totalis, and alopecia universalis over a 24-week period, but longer studies are needed to assess long-term safety.

This study observed initial hair regrowth in a businessman with alopecia areata universalis treated with tofacitinib, but the effect diminished, leading to renewed hair loss.

This study concluded that oral tofacitinib significantly improved symptoms in patients with lichen planus pigmentosus who did not respond to conventional treatments, showing it as a viable alternative.

This study evaluated the effectiveness and safety of ritlecitinib in patients aged 12 or older with alopecia totalis or universalis, finding higher hair regrowth response rates compared to placebo at 24 weeks, with continued improvement and acceptable safety through 48 weeks.

This systematic review explored the potential of cetirizine, an anti-inflammatory antihistamine, as a complementary treatment for androgenetic alopecia, reporting that it might help prevent hair follicle miniaturization by reducing inflammation and modulating immune activity, without notable side effects.

This case report describes significant therapeutic effects from Tofacitinib Citrate Sustained-Release Tablets in a patient with Alopecia Areata, while highlighting the economic burden of long-term treatment.

In this animal study, atorvastatin co-administered with trastuzumab reversed trastuzumab-induced cognitive impairment (chemo-brain) and improved its anti-cancer efficacy without causing hair loss.

In this retrospective study, tofacitinib showed promise as a treatment for alopecia areata, with 46.5% of patients experiencing a very good response and minimal adverse effects, suggesting it could be a primary option for moderate to severe cases.

This study explored the in vitro skin penetration of two compounds from Tectona grandis leaf extract used for standardization and found that compound 1 penetrates more efficiently than compound 2, especially with a propylene glycol enhancer.

This study reports that oral tofacitinib treatment in a patient with refractory lichen planus pigmentosus and frontal fibrosing alopecia resulted in near-complete resolution of hyperpigmentation and cessation of hairline recession over 18 months, and suggests it may be a promising therapy for these challenging conditions.

In this open-label trial, tofacitinib showed dramatic clinical responses in most patients with moderate-to-severe alopecia areata, supporting further research into JAK inhibitors for this condition.

This study concluded that a green tea extract hair tonic was stable, promoted more hair growth than 2.5% minoxidil, and did not cause skin irritation.

This case report describes a 43-year-old male patient with alopecia totalis successfully regaining all his hair after six months of treatment with tofacitinib, with no relapse observed after one year.

In this study, tibial cortex transverse transport accelerated wound healing in diabetic rats, potentially through enhanced mobilization of non-classical monocytes and increased M2 macrophage polarization.

This review explores the mechanisms and clinical applications of thymosin β4, highlighting its potential in various medical fields, but it presents no new research findings.

In this clinical trial, Tofacitinib effectively promoted hair regrowth in patients with alopecia areata, alopecia totalis, and alopecia universalis, with 75.6% experiencing no side effects, making it a promising treatment option according to the study.